236 related articles for article (PubMed ID: 33742783)
1. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure.
Sathe AG; Brundage RC; Ivaturi V; Cloyd JC; Chamberlain JM; Elm JJ; Silbergleit R; Kapur J; Coles LD
Clin Transl Sci; 2021 Jul; 14(4):1444-1451. PubMed ID: 33742783
[TBL] [Abstract][Full Text] [Related]
2. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
Sathe AG; Mishra U; Ivaturi V; Brundage RC; Cloyd JC; Elm JJ; Chamberlain JM; Silbergleit R; Kapur J; Lowenstein DH; Shinnar S; Cock HR; Fountain NB; Babcock L; Coles LD
J Clin Pharmacol; 2021 Jun; 61(6):763-768. PubMed ID: 33336359
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.
Johannessen Landmark C; Heger K; Lund C; Burns ML; Bjørnvold M; Sætre E; Johannessen SI
Ther Drug Monit; 2020 Oct; 42(5):744-753. PubMed ID: 32558674
[TBL] [Abstract][Full Text] [Related]
4. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
[TBL] [Abstract][Full Text] [Related]
5. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation and implications of dried blood spot sampling of carbamazepine, valproic acid and phenytoin in patients with epilepsy.
Kong ST; Lim SH; Lee WB; Kumar PK; Wang HY; Ng YL; Wong PS; Ho PC
PLoS One; 2014; 9(9):e108190. PubMed ID: 25255292
[TBL] [Abstract][Full Text] [Related]
7. The influence of sparse data sampling on population pharmacokinetics: a post hoc analysis of a pharmacokinetic study of morphine in healthy volunteers.
Ariano RE; Duke PC; Sitar DS
Clin Ther; 2012 Mar; 34(3):668-76. PubMed ID: 22381713
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework.
Centanni M; Reijnhout N; Thijs A; Karlsson MO; Friberg LE
Clin Pharmacokinet; 2024 Jun; 63(6):871-884. PubMed ID: 38842789
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
Coupez R; Nicolas JM; Browne TR
Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
[TBL] [Abstract][Full Text] [Related]
10. Predictive Performance of Population Pharmacokinetic Models of Levetiracetam in Children and Evaluation of Dosing Regimen.
Tauzin M; Tréluyer JM; Nabbout R; Chemaly N; Billette de Villemeur T; Desguerre I; Lui G; Gana I; Boujaafar S; Zheng Y; Benaboud S; Bouazza N; Chenevier-Gobeaux C; Freihuber C; Hirt D
J Clin Pharmacol; 2021 Oct; 61(10):1366-1375. PubMed ID: 33997989
[TBL] [Abstract][Full Text] [Related]
11. Predictive ability of published population pharmacokinetic models of valproic acid in Thai manic patients.
Methaneethorn J; Leelakanok N
J Clin Pharm Ther; 2021 Feb; 46(1):198-207. PubMed ID: 32986889
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.
Collins JW; Heyward Hull J; Dumond JB
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):631-640. PubMed ID: 29119381
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus.
Brigo F; Bragazzi N; Nardone R; Trinka E
Epilepsy Behav; 2016 Nov; 64(Pt A):110-115. PubMed ID: 27736657
[TBL] [Abstract][Full Text] [Related]
14. Nomogram for the prediction of unbound phenytoin concentrations in patients on a combined treatment of phenytoin and valproic acid.
May TW; Rambeck B; Nothbaum N
Eur Neurol; 1991; 31(1):57-60. PubMed ID: 2015840
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.
Mei S; Feng W; Zhu L; Li X; Yu Y; Yang W; Gao B; Wu X; Fang F; Zhao Z
Eur J Clin Pharmacol; 2018 Aug; 74(8):1029-1036. PubMed ID: 29666902
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling.
Gustavsen MT; Midtvedt K; Vethe NT; Robertsen I; Bergan S; Åsberg A
Ther Drug Monit; 2020 Jun; 42(3):407-414. PubMed ID: 31479042
[TBL] [Abstract][Full Text] [Related]
17. A comparison of four antiepileptic drugs in status epilepticus: experience from India.
Misra UK; Kalita J
Int J Neurosci; 2016 Nov; 126(11):1013-9. PubMed ID: 26456955
[TBL] [Abstract][Full Text] [Related]
18. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent interaction between phenytoin and valproic acid.
Riva R; Albani F; Contin M; Perucca E; Ambrosetto G; Gobbi G; Santucci M; Procaccianti G; Baruzzi A
Neurology; 1985 Apr; 35(4):510-5. PubMed ID: 3920548
[TBL] [Abstract][Full Text] [Related]
20. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
